Association of heightened host and tumor immunity with prolonged duration of response to checkpoint inhibition across solid tumors
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Predicting cancer immunotherapy success is challenging. This study found that higher predicted neoantigens and specific rare gene variants, like in EPHA8, correlate with longer patient response to immunotherapy.
Area Of Science
- Oncology
- Immunology
- Genetics
Background
- Cancer immunotherapy offers significant benefits but lacks reliable predictive biomarkers for diverse tumor types.
- Identifying factors that predict patient response to immunotherapy is crucial for optimizing treatment strategies.
Purpose Of The Study
- To investigate the role of predicted neoantigens and genetic variants in predicting clinical benefit from cancer immunotherapy.
- To explore the association between neoantigen load, immune responses, and patient outcomes in advanced solid tumors.
Main Methods
- DNA and RNA-based analyses were performed on a cohort of 88 patients with advanced solid tumors.
- Immune responses were assessed by measuring predicted neoantigens, HLA binding potential, cytotoxic markers, and T cell activity.
- Genetic analysis focused on identifying rare variants associated with prolonged immunotherapy duration.
Main Results
- Patients with prolonged immunotherapy (>12 months) showed higher levels of predicted neoantigens with strong HLA binding.
- Elevated cytotoxic markers and enhanced T cell activity were observed in patients with longer treatment duration.
- Rare variants, particularly within the EPHA8 gene, were exclusively found in patients with prolonged immunotherapy response and are evolutionarily conserved.
Conclusions
- Predicted neoantigens and specific rare genetic variants may serve as potential biomarkers for immunotherapy response.
- Understanding the molecular and immunological mechanisms can help refine personalized cancer treatment strategies.
- Further research with larger cohorts is needed to validate these findings and their clinical utility.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Overview
The cell-mediated immune system is the host’s primary response against invasive bacteria and viruses that cause intracellular infections. It is also essential for fighting against and destroying cancer cells. Furthermore, the cell-mediated immune system plays a role in the rejection of organ transplants or graft tissue.
The Innate Immune System Activates the Adaptive Immune System
Phagocytic cells of the innate immune system, such as macrophages or dendritic cells, are the...
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
The T and B lymphocytes of the adaptive immune system develop from common lymphoid progenitor cells in the bone marrow. These progenitors give rise to precursors that eventually develop into both T and B lymphocytes. As these precursors mature, they gain the ability to detect and respond to foreign antigens in the body, a process known as immunocompetence. Additionally, these precursors acquire self-tolerance, a process that ensures they do not react to self-antigens. This intricate system...